[InformedRx™- Eliminating Risk: Why Managing Genetic-Driven Therapies for Rare Diseases Is Critical]

More than 70% of new gene therapies in development target rare diseases, half of which affect children. But as the growth of genetic therapies designed to treat these rare conditions continues to climb, the need for expert guidance around who should receive these therapies has intensified. Decisions around genetic-driven therapies leave little margin for error. …

[InformedRx™- Eliminating Risk: Why Managing Genetic-Driven Therapies for Rare Diseases Is Critical] Read More »